If you have been reading about alpha-MSH and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-13. Numbers and descriptions here follow the published literature rather than marketing material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | No marketing authorization in major jurisdictions |
| Scheduling example | Prescription-only supply in some countries | Handled as an unlicensed medicine where restricted |
| Sports classification | Prohibited peptide | Appears on anti-doping prohibited lists |
| Reported presentation | Lyophilized vial | Nominal content varies between vendors |
| Detection approach | Liquid chromatography–tandem mass spectrometry | Used in anti-doping and forensic testing |
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
Solid peptide kept dry at minus twenty degrees Celsius, shielded from light and moisture, is generally considered stable for extended periods. Solutions are divided into single-use aliquots and held at minus twenty or minus eighty degrees Celsius, because repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. Hydrolysis of the backbone and oxidation of tryptophan are the principal degradation routes in aqueous solution, and both accelerate at ambient temperature. Hygroscopic uptake after a vial is opened can also shift the actual mass weighed, which affects any concentration calculated from it.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
== History == Use of barrier membranes to direct bone regeneration was first described in the context of orthopaedic research 1959. The theoretical principles basic to guided tissue regeneration were developed by Melcher in 1976, who outlined the necessity of excluding unwanted cell lines from healing sites to allow growth of desired tissues. Based on positive clinical results of regeneration in periodontology research in the 1980s, research began to focus on the potential for re-building alveolar bone defects using guided bone regeneration. The theory of Guided tissue regeneration has been challenged in dentistry. The GBR principle was first examined by Dahlin et al. in 1988 on rats. In 1988, Swiss oral and maxillofacial surgeon Daniel Buser performed one of the first documented Guided Bone Regeneration procedures at the University of Bern. The selective ingrowth of bone-forming cells into a bone defect region could be improved if the adjacent tissue is kept away with a membrane; this was confirmed in a study by Kostopoulos and Karring in 1994. GBR can be used for bone regeneration on exposed implant coils .
=== Mechanism of action === Tramadol induces analgesic effects through a variety of different targets on the noradrenergic system, serotonergic system, and opioid receptors system. Tramadol affects serotonin and norepinephrine reuptake inhibition similarly to certain antidepressants known as serotonin–norepinephrine reuptake inhibitors (SNRIs), such as venlafaxine and duloxetine. Tramadol exists as a racemic mixture, the positive enantiomer inhibits serotonin reuptake while the negative enantiomer inhibits noradrenaline re-uptake, by binding to and blocking the transporters. Both enantiomers of tramadol are agonists of the μ-opioid receptor and its M1 metabolite, O-desmetramadol, is also a μ-opioid receptor agonist but is 6 times more potent than tramadol itself. All of these actions may work synergistically to induce analgesia.
Djalikatou Diallo- former vice-president Guinean Football Federation, former vice-president Nation Assembly, former Minister of National unity and Citizenship. Diaka Sidibé- former Minister of Higher Education, Scientific Research and Innovation, former Minister of Trade, Industry and Small and Medium-sized Enterprises. Kadiatou Émilie Diaby - former Minister of Public Works. Ibrahima Abé Sylla - Minister of Energy, Hydropower and Hydrocarbons, Guinea. Aïssatou Bobo Baldé - former vice president National Assembly. Barry Diawadou – Civil clerk and politician, former member of the French National Assembly and former Minister of Education. Guinea Mamoudou Nagnalen Barry - former minister of Agriculture. Sidibé Fatoumata Kaba (diplomat) - former minister of foreign affairs, former permanent Representative to the African union And The United Nations, former ambassador to Nigeria, Ethiopia. Ambassador to the united states, Guinea. Mama Kanny Diallo - Economist, former Minister of Planning and Economic Development, Guinea. Saifoulaye Diallo –Politician and lawmaker, former member of the French National Assembly, former president of the Territorial Assembly and President of the National Assembly; former Minister of State (foreign affairs, finance, social services). Elhadj Gando Barry - former Minister of Infrastructure and Public Works, CEO Électricité de Guinée. Ibrahima Barry (popularly known as Barry III) – Lawyer and politician, former Minister from Guinea Oumar Diouhé Bah - Minister of Health and public hygiene, Guinea.
=== Copulation === Copulation begins as the males use their chelicerae to rapidly move back and forth across the female's ventral body surface. This is an attempt to grab hold of the female's body and mount onto their epigyne. For some males, it can take up to 100 attempts to properly mount. Once mounted, the males pull the females closer to them resulting in rotation of the female opisthosoma from a horizontal to vertical position. At this point, the male is able to insert his pedipalps into the genital cavity of the female. During the multiple insertions, the male pedipalps are twisted into different motions in a synchronous fashion with the procursi being inserted deeply into the female genital cavity to release sperm into the uterus externus. As the coupling duration lengthens, the amount of palpal insertions decreases. The duration of copulation is dependent upon whether or not the female P. phalangioides have previously mated with any males. If the females have mated, second males are only allowed to engage in copulation for a few minutes. On the other hand, first males are able to copulate for anywhere between 16 and 122 minutes. Once the mating has finished, the females often act aggressively towards the males in an attempt to drive them off.
Upon taking office in 2001, Bush stated his opposition to the Kyoto Protocol, an amendment to the United Nations Framework Convention on Climate Change which seeks to impose mandatory targets for reducing greenhouse gas emissions, citing that the treaty exempted 80% of the world's population and would have cost tens of billions of dollars per year. He also cited that the Senate had voted 95–0 in 1997 on a resolution expressing its disapproval of the protocol. In May 2001, Bush signed an executive order to create an interagency task force to streamline energy projects, and later signed two other executive orders to tackle environmental issues. In 2002, Bush proposed the Clear Skies Act of 2003, which aimed at amending the Clean Air Act to reduce air pollution through the use of emissions trading programs. Many experts argued that this legislation would have weakened the original legislation by allowing higher emission rates of pollutants than were previously legal. The initiative was introduced to Congress, but failed to make it out of committee. Later in 2006, Bush declared the Northwestern Hawaiian Islands a national monument, creating the largest marine reserve to date. The Papahānaumokuākea Marine National Monument comprises 84 million acres (340,000 km2) and is home to 7,000 species of fish, birds, and other marine animals, many of which are specific to only those islands. The move was hailed by conservationists for "its foresight and leadership in protecting this incredible area".
Sources: en.wikipedia.org
The residues of Gln94, Arg96, and His148 are able to stabilize by delocalizing the chromophore charge. Arg96 is the most important stabilizing residue due to the fact that it prompts the necessary structural realignments that are necessary from the HBI ring to occur. Any mutation to the Arg96 residue would result in a decrease in the development rate of the chromophore because proper electrostatic and steric interactions would be lost. Tyr66 is the recipient of hydrogen bonds and does not ionize in order to produce favorable electrostatics.
The maximum temperature is limited to that at which the stationary phase is stable. C18 bonded phases which are common in HPLC seem to be stable at temperatures up to 200 °C, far above that of pure silica, and polymeric styrene–divinylbenzene phases offer similar temperature stability.
=== Current AI methods and databases of predicted protein structures === AlphaFold2, was introduced in CASP14, and is capable of predicting protein structures to near experimental accuracy. AlphaFold was swiftly followed by RoseTTAFold and later by OmegaFold and the ESM Metagenomic Atlas. In a study, Sommer et al. 2022 demonstrated the application of protein structure prediction in genome annotation, specifically in identifying functional protein isoforms using computationally predicted structures, available at https://www.isoform.io. This study highlights the promise of protein structure prediction as a genome annotation tool and presents a practical, structure-guided approach that can be used to enhance the annotation of any genome. In 2024, David Baker and Demis Hassabis (along with John M. Jumper) were awarded the Nobel Prize in Chemistry for their contributions to computational protein modeling, including the development of AlphaFold2, an AI-based model for protein structure prediction. AlphaFold2's accuracy has been evaluated against experimentally determined protein structures using metrics such as root-mean-square deviation (RMSD). The median RMSD between different experimental structures of the same protein is approximately 0.6 Å, while the median RMSD between AlphaFold2 predictions and experimental structures is around 1 Å. For regions where AlphaFold2 assigns high confidence, the median RMSD is about 0.6 Å, comparable to the variability observed between different experimental structures.
=== Novel mAb development technology === Several monoclonal antibody technologies were developed in the period from the 1970s to the late 2010s, such as phage display, single B cell culture, single cell amplification from various B cell populations and single plasma cell interrogation technologies. Different from traditional hybridoma technology, the more recent technologies use molecular biology techniques to amplify the heavy and light chains of the antibody genes by PCR and produce in either bacterial or mammalian systems with recombinant technology. One of the advantages of the new technologies is their applicability to multiple animals, such as rabbit, llama, chicken and other common experimental animals in the laboratory.
Photoinduction takes place with a brief exposure to light (wavelength is tetrazole-dependent) to minimize photodamage to cells. The reaction is enhanced in aqueous conditions and generates a single regioisomer. The transient nitrile imine is highly reactive for 1,3-dipolar cycloaddition due to a bent structure which reduces distortion energy. Substitution with electron-donating groups on phenyl rings increases the HOMO energy, when placed on the 1,3 nitrile imine and increases the rate of reaction. Advantages of this approach include the ability to spatially or temporally control reaction and the ability to incorporate both alkenes and tetrazoles into biomolecules using simple biological methods such as genetic encoding. Additionally, the tetrazole can be designed to be fluorogenic in order to monitor progress of the reaction.
Sources: en.wikipedia.org
=== EC 1.5.98 With other, known, physiological acceptors === EC 1.5.98.1: ethylenetetrahydromethanopterin dehydrogenase EC 1.5.98.2: 5,10-methylenetetrahydromethanopterin reductase EC 1.5.98.3: coenzyme F420:methanophenazine dehydrogenase
== Further reading == Theravada Walpola Rahula (1974), What the Buddha Taught P. A. Payutto, Dependent Origination: The Buddhist Law of Conditionality (translation for the fourth chapter of P. A. Payutto's Buddhadhamma) Ajahn Sucitto (2010). Turning the Wheel of Truth: Commentary on the Buddha's First Teaching. Shambhala. (pages 61–76) Jackson, Peter A. (2003), Buddhadasa. Theravada Buddhism and Modernist reform in Thailand, Silkworm Books Ajahn Amaro (2021), Catastrophe/Apostrophe: The Buddha's Teachings on Dependent Origination/Cessation, Amaravati Publications Tibetan Buddhism Chogyam Trungpa (1972). "Karma and Rebirth: The Twelve Nidanas, by Chogyam Trungpa Rinpoche." Karma and the Twelve Nidanas, A Sourcebook for the Shambhala School of Buddhist Studies. Vajradhatu Publications. Dalai Lama (1992). The Meaning of Life, translated and edited by Jeffrey Hopkins, Boston: Wisdom. Geshe Sonam Rinchen (2006). How Karma Works: The Twelve Links of Dependent Arising. Snow Lion Khandro Rinpoche (2003). This Precious Life. Shambala Thrangu Rinpoche (2001). The Twelve Links of Interdependent Origination. Nama Buddha Publications. Scholarly Frauwallner, Erich (1973), "Chapter 5. The Buddha and the Jina", History of Indian Philosophy: The philosophy of the Veda and of the epic. The Buddha and the Jina. The Sāmkhya and the classical Yoga-system, Motilal Banarsidass Bucknell, Roderick S.
=== G protein-coupled receptor inverse agonists === Two known endogenous inverse agonists are the Agouti-related peptide (AgRP) and its associated peptide Agouti signalling peptide (ASIP). AgRP and ASIP appear naturally in humans and bind melanocortin receptors 4 and 1 (Mc4R and Mc1R), respectively, with nanomolar affinities. The opioid antagonists naloxone and naltrexone act as neutral antagonists of the mu opioid receptors under normal conditions, but as inverse agonists when chronic exposure to opioids has increased the basal activity of the mu opioid receptors. 6α-naltrexo, 6β-naltrexol, 6β-naloxol, and 6β-naltrexamine acted neutral antagonists regardless of opioid binding and caused significantly reduced withdrawal jumping when compared to naloxone and naltrexone. Nearly all antihistamines acting at H1 receptors and H2 receptors have been shown to be inverse agonists. The beta blockers carvedilol and bucindolol have been shown to be low level inverse agonists at beta adrenoceptors.
The elements on the periodic table were originally arranged in order of increasing atomic weight. However, in a number of places chemists chose to swap the positions of certain adjacent elements so that they appeared in a group with other elements with similar properties. For instance, tellurium is placed before iodine even though tellurium is heavier (127.6 vs 126.9) so that iodine can be in the same column as the other halogens. The modern periodic table is based on atomic number, which is equivalent to the nuclear charge, a change that had to wait for the discovery of the nucleus. In addition, an entire row of the table was not shown because the noble gases had not been discovered when Mendeleev devised his table.
== Justification == Topical drug delivery is a route of administering drugs via the skin with the intent to provide therapeutic effects. This system usually provides a local effect on certain organs. In ancient times, people used herbs on wounds for relieving the inflammatory effect or as pain relievers. There are numerous dosage forms that can be used topically, including cream, ointment, lotion, patches, and other forms. The topical use has many advantages: avoiding first pass metabolism which can increase its bioavailability, being convenient and easy to apply to a large area, being easy to terminate the medication, and avoiding gastrointestinal irritations. All these can increase patient compliance. However, there are several disadvantages to this system – causing skin irritations and symptoms like rashes and itchiness may occur. Also, only small particles can pass through the skin, which limits the choice of drugs. Since skin is the main medium of the topical drug delivery system, its conditions determine the rate of skin penetration leading to affecting the pharmacokinetics of the drug. The temperature, pH value, and dryness of the skin need to be considered. There are some novel topical drugs in the market which can utilise the system as much as possible. This localized system provides topical therapeutic effects via skin, eyes, nose, and vagina to treat diseases. The most common usage is for local skin infections.
Sources: en.wikipedia.org
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.
The peptide is listed as prohibited in competitive sport, so laboratories develop detection methods and monitor for its presence. Its appearance in enforcement reports reflects that classification rather than any approved athletic use. Analytical work in this area focuses on identifying the molecule and its breakdown products in biological samples.
Chromatographic separation combined with mass spectrometry identifies the peptide and estimates its amount in a sample. Testing can confirm whether the expected molecule is present and at what concentration. It cannot establish how a product was manufactured or whether it meets any purity standard.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.